Interaction of a thrombin inhibitor and a platelet GP IIb/IIIa antagonist in vivo: Evidence that thrombin mediates platelet aggregation and subsequent thromboxane A2 formation during coronary thrombolysis

Journal of Pharmacology and Experimental Therapeutics

Volumn 281, Issue 3, 1997, Pages 1178-1185

  Pratico, Domenico ^a,b   Murphy, Natalie P ^a   Fitzgerald, Desmond J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DINORTHROMBOXANE B2; ADENOSINE DIPHOSPHATE; ALTEPLASE; CREATININE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; NAPSAGATRAN; PROTHROMBIN; THROMBIN; THROMBIN INHIBITOR; THROMBOPLASTIN; THROMBOXANE A2; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY ARTERY THROMBOSIS; CORONARY REPERFUSION; DOG; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ACETATES; ANIMALS; ANTITHROMBINS; CORONARY VESSELS; DOGS; DRUG INTERACTIONS; NAPHTHALENES; PIPERIDINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBIN; THROMBOXANE A2; TYROSINE;

EID: 0030999569     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. BERGSDORK, N., NILSSON, T. AND WAILEN, P.: An enzyme linked immunoabsorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb. Haemostas. 30: 740-744, 1983.
2. BRASS, L. F., HOXIE, J. A., KIEBER-EMMONS, T., MANNING, D. R., PONCZ, M. AND WOOLKALIS, M.: Agonist receptors and G proteins as mediators of platelet activation. Adv. Exp. Med. Biol. 344: 17-36, 1993.
3. 2 formation. J. Biol. Chem. 266: 19232-19237, 1991.
4. CARTEAUX, J. P., GAST, A., TSCHOPP, T. B. AND ROUX, S.: Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis. Circulation 91: 1568-1574, 1995.
5. CARTEAUX, J. P., STEINER, B. AND ROUX, S.: Ro 44-9883, a new non-peptidic GP IIb/IIIa antagonist, prevents platelet loss in a guinea pig model of extracorporeal circulation. Thromb. Haemostas. 70: 817-821, 1993.
6. COLLER, B. S.: Platelets and thrombolytic therapy. N. Engl. J. Med. 322: 33-42, 1990
7. EISENBERG, P. R., SHERMAN, L. A. AND JAFFE, A. S.: Paradoxic elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysis. J. Am. Coll. Cardiol. 10: 527-529, 1987.
8. 2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc. Natl. Acad. Sci. U.S.A. 86: 7585-7589, 1989.
9. FITZGERALD, D. J., CATELLA, F., ROY, L. AND FITZGERALD. G. A.: Marked platelet activation in vivo after intravenous streptokinase. Circulation 77: 142-150, 1988.
10. FITZGERALD, D. J., HANSON, M. AND FITZGERALD, G. A.: Systematic lysis protects against the effects of platelet activation during coronary thrombolysis. J. Clin. Invest. 88: 1589-1595, 1991.
11. 2 modulate the response to tissue-type plasminogen activator in vivo. Circ. Res. 65: 83-94, 1989.
12. FITZGERALD, G. A., PEDERSEN, A. K. AND PATRONO, C.: Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67: 1174, 1983.
13. GALVANI, M., ABENDSCHEIN, D. R., FERRINI, D., OTTANI, F., RUSTICALI, F. AND EISENBERG, P. R.: Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase. J. Am. Coll. Cardiol. 24: 1445-1452, 1994.
14. GAST, A., TSCHOPP, T. B., SCHMID, G., HILPERT, K. AND ACKERMANN, J.: Inhibition of clot-bound and free (fluid-phase) thrombin by a novel synthetic thrombin inhibitor (Ro46-6240), recombinant hirudin and heparin in human plasma. Blood Coag. & Fibrinolysis 5: 879-887, 1994.
15. GOLD, H. K., COLLER, B. S., YASUDA, T., SAITO, T., FALLON, J. T., GUERRERO, J. L., LEINBACH, R. C., ZISKIND, A. A. AND COLLEN, D.: Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GP IIb/IIIa antibody in a canine preparation. Circulation 77: 670-677, 1988.
16. 2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 77: 678-684, 1988.
17. HAMBERG, M., SVENSSON, J. AND SAMUELSSON, B.: Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. U.S.A. 72: 2994-2998, 1975.
18. ISIS-2 (Second international study of infarct survival) collaborative group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction ISIS-2. Lancet 2: 349-650, 1988.
19. JANG, I. K., GOLD, H. K., LEINBACH, R. C., FALLON, J. T. AND COLLEN, C.: In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ. Res. 67: 1552-1561, 1990.
20. KERINS, D. M., ROY, L., FITZGERALD, G. A. AND FITZGERALD, D. J.: Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. Circulation 80: 1718-1729, 1989.
21. KOUNS, W. C., KIRCHHOFER, D., HADVARY, P., EDENHOFER, A., WELLER, T., PFENNINGER, G., BAUMGARTNER, H. R., JENNINGS, L. K. AND STEINER, B.: Reversible conformational changes induced in glycoprotein IIb-IIIa by a potent and selective peptidomimetic inhibitor. Blood 80: 2539-2547, 1992.
22. MERLINI, P. A., BAUER, K. A., OLTRONA, L., ARDISSINO, D., SPINOLA, A., CATTANEO, M., BROCCOLINO, M., MANNUCCI, P. M. AND ROSENBERG, R. D.: Thrombin generation and activity during thrombolysis and concomitant heparin therapy in patients with acute myocardial infarction. J. Am. Coll. Cardiol. 25: 203-209, 1995.
23. MICKELSON, J. K., SIMPSON, P. J., CRONIN, M., HOMEISTER, J. W., LAYWELL, E., KITZEN, J. AND LUCHESSI, B. R.: Antiplatelet antibody [7E3F(ab′)2] prevents rethrombosis after recombinant tissue-type plasminogen activator-induced coronary artery thrombolysis in a canine model. Circulation 81: 617-627, 1990.
24. NICOLINI, F. A., LEE, P., RIOS, G., KOTTKE-MARCHANT, K. AND TOPOL, E. J.: Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 89: 1802-1809, 1994.
25. 2 and thrombin receptors in human platelets. Proc. Natl. Acad. Sci. U.S.A. 91: 504-508, 1994.
26. RUDD, M. A., GEORGE, D., JOHNSTONE, M. T., MOOR, R. T., COLLINS, L., RABBANI, L. E. AND LOSCALZO, J.: Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. Circ. Res. 70: 929-934, 1992.
27. FAK in platelets requires coordinated signaling through integrin and agonist receptors. J. Biol. Chem. 269: 14738-14745, 1994.
28. SITKO, G. R., RAMJIT, D. R., STABILITO, I. I., LEHMAN, D., LYNCH, J. J. AND VLASUK, G. P.: Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 85: 805-815, 1992.
29. 2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. Circulation 86: 1993-1999, 1992.